Familial hypercholesterolemia is a metabolic disorder inherited as an autosomal dominant trait characterized by an increased plasma low density lipoprotein (LDL) level. It has been demonstrated that the disease is caused by several different mutations in the LDL receptor gene. Although early identification of individuals carrying the defective gene could be useful in reducing the risk of atherosclerosis and myocardial infarction, the available techniques for determining the number of the functional LDL receptor molecules are not sufficiently accurate. The recent isolation of the LDL receptor gene now makes it possible to use restriction fragment length polymorphisms to study the inheritance of the defective allele in families with familial hypercholesterolemia. In the present study, we report the use of a Pvu II restriction fragment length polymorphism to follow the inheritance of familial hypercholesterolemia in a total of 79 patients from 37 different families. This restriction fragment length polymorphism allowed unequivocal diagnosis in 32.5% of the cases. Furthermore, in the Italians studied, the absence of a polymorphic Pvu II cutting site (P1 allele) was found to be strongly associated with familial hypercholesterolemia. (Arteriosclerosis 8:845-850 November/December 1988) F amilial hypercholesterolemia (FH) is a metabolic disorder characterized by a raised plasma low density lipoprotein (LDL) concentration, xanthomas of skin and tendons, and premature atherosclerosis. The disease is inherited as an autosomal dominant trait with a heterozygote frequency of about 1 in 500 in Europeans and Americans. Heterozygosity is associated with a high risk of myocardial infarction in the fourth decade of life. Homozygotes are much more severely affected and often experience myocardial infarction in the first or second decade.
Over the past few years, it has been clearly demonstrated that the primary defect in FH is a mutation in the gene coding for the LDL receptor that prevents a normal clearance of plasma LDL. 1 Several reports have recently detailed some of these mutations that affect different parts of the gene. 2 -5 Early identification of FH heterozygotes, especially in those cases where the cholesterol level overlaps that of normal subjects, is highly desirable so that the risk of future myocardial infarction can be reduced by diet and life style change. However, the techniques currently available for determining the number of functional LDL recep-tor molecules on cultured cells are not accurate enough to give unambiguous results.
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The recent isolation of a cDNA clone for the human LDL receptor gene has now made it possible to investigate the presence of restriction fragment length polymorphisms (RFLPs), which can be used for early diagnosis of FH. 9 Some RFLPs of the LDL receptor gene that might be used to follow the inheritance of the affected gene in informative families have been found. Thus, Humphries et al. 10 -11 and Leppert et al. 12 have recently shown that the two alleles defined by a polymorphic Pvu II site located in the intron between exons 15 and 16 cosegregate with the disease in informative families.
In the present study, we report the distribution of the Pvu II alleles in 112 normolipidemic Italian subjects ages 2 to 99 years old and in 79 FH patients from 37 different families.
Methods Subjects
The subjects were selected according to the following criteria: Normolipidemic controls had cholesterol levels <5.2 mmol/l with LDL cholesterol <3.5 mmol/l (younger than 30 years old); cholesterol levels s5.7 mmol/l with LDL cholesterol <4.0 mmol/l (30 years old or older); triglyceride levels s i . 8 mmol/l; negative family history of hyperlipidemias, coronary heart disease, or other clinical signs of atherosclerosis. FH patients had cholesterol levels s6.7 mmol/l with LDL >4.6 mmol/l (younger than 16 years old); cholesterol levels s7.5 mmol/l with LDL >5.2 mmol/l (16 years old or older); a total triglyceride level not exceeding 2 mmol/l; plus two of the following: tendon xanthomas in the proband or in one or more first degree relatives, hypercholesterolemic children in the family, cholesterol levels s7.5 mmol/l in two or more family members, and family history of coronary heart disease in one or more first or second degree relatives younger than 50 years old.
All the subjects gave their informed consent for this study.
Laboratory Analyses
DNA was prepared from 10 ml of fresh whole blood by a sodium dodecyl sulfate (SDS) lysis method. 13 DNA was digested with the Pvu II restriction enzyme, according to the manufacturer's directions (Bethesda Research Laboratories, Gibco BRL, Scotland). DNA fragments were separated by size on a 0.8% agarose gel and were transferred to Gene Screen Plus filters (New England Nuclear, Du Pont, West Germany) by the Southern blotting technique.
14 The LDL receptor probe, pLDLR-2HH1, kindly provided by David W. Russell, is a 1.9 kb fragment (bp 1573 to 3486) of the 3' end of the LDL receptor cDNA clone. The fragment was excised from a 1 % low melting agarose gel and was labeled by the nick translation technique with 32 p(a)dCTP at 3000 Ci/mmol (Amersham International, England).
13 5 x 10 6 cpm/ml of the probe was incubated with filters for 36 hours at 65°C in a 6x SSC, 1 % SDS, 5 x Denhart, 100 /ug/ml herring DNA solution. Filters were washed with 0.2 x SSC, 1% SDS at 65°C and exposed to X-ray film (Kodak Xomat AR) for 2 to 4 days at -80°C.
Statistical Analyses
Statistical comparison of allele frequencies was done by the chi-squared test. The polymorphism information content was calculated according to the method of Botstein et al. 15 16.5 kb 14
Results
As previously described, 1016 digestion with Pvu II generates three different fragment patterns in normal subjects ( Figure 1 ). One fragment (3.6 kb) is common to all individuals, while the 16.5 and 14.0 kb derive from two different alleles (P1 and P2, respectively). The polymorphic Pvu II site has been located in the intron separating exon 15 and 16 and is due to an adenine-to-guanine transition in the right arm of the 5' Alu repeat of a cluster of two tandem Alu sequences. 16 The frequencies of the two alleles were determined in 112 unrelated normolipidemic Italian individuals ages 2 to 99 years old (mean age 41.2 years) who had plasma cholesterol, 4.61 ±0.53 mmol/l; LDL cholesterol, 2.75±0.67 mmol/l; and triglyceride 0.92±0.39 mmol/l. Table 1 reports the observed frequencies and the distribution of genotypes, which are close to the expected values if the population is in Hardy-Weinberg equilibrium. Table 1 also reports a comparison with the frequencies observed in previous studies in different populations. It is evident that, in the Italian population, the two alleles are more evenly represented, since the frequency of allele P2 (0.402) was nearly twice that in the English population (0.226). Afrikaners 17 are, in this respect, more similar to 2.5 Italians than to English (0.346). Analysis of the allele frequencies with the chi-squared test showed that the difference between the Italian and English populations is statistically significant (# 2 =11.03, p<0.005). The Pvu II RFLP was then determined in 79 individuals with heterozygous FH from 37 different families, ages 3 to 66 years old (mean age 40.9 years) who had plasma cholesterol, 9.31 ±1.76 mmol/l; LDL cholesterol, 7.38± 1.79 mmol/l; triglyceride, 1.18±0.46 mmol/l. An abnormal restriction fragment, which was associated with the disease and which could not be assigned to either the P1 or the P2 allele, was observed in two families. The frequencies of the two alleles were estimated in the remaining 35 unrelated patients. As reported in Table 2 , FH was strongly associated with the P1 allele at a frequency of 0.786. The P1P1 genotype (57.1 % of probands, 58.9% of all patients) was more frequent than in the normal population (35.7%), while the P2P2 was not found. Statistical analysis showed that the frequencies of the alleles in the FH proband group was significantly different from that of normal controls (* 2 =8.17, p<0.005).
Only 25 of the 35 probands had a sufficient number of family members available for study. When the RFLP was used to follow the inheritance of the LDL receptor gene in these 25 FH families, the disease was found to unambiguously cosegregate with the P1 allele in 23 families (Table 3 ). Figure 2 shows the complete pedigree of seventeen families. Table 4 summarizes the independent haplotypes found in the 25 families. This finding had already been reported, 10 but was not considered significant because of the low frequency (20%) of the P2 allele in the English population and the small number (two) of families examined.
In our study, with the observed frequency of P2 in the Italian population (0.402, see Table 2 ), one would expect that in 40% (10 of 23) of informative families the FH phenotype would segregate with P2.
Discussion
A number of recent reports indicate that the mutation in the LDL receptor gene in FH patients is not unique. 2 " 5 Thus, several different mutations, often involving the multitude of Alu sequences present in the gene, have been found in different families with FH. However, in most cases, even several restriction enzymes have failed to demonstrate any abnormality in the restriction fragments, either because the deletion involved was too small or because a point mutation was responsible for the defect. Thus, in our study, we found an abnormal restriction fragment inherited with the disease in only 2 of the 37 families examined (data not shown). Both mutations appeared in a preliminary characterization to be different from the ones already described. (These will be reported in detail elsewhere.) It seems unlikely then, that a restriction pattern characteristic of FH that could be used to unequivocally diagnose the disease can be found. Nevertheless, once the allele of the affected gene is identified, the RFLP generated by the polymorphic Pvu II site between exons 15 and 16 of the LDL receptor gene can be used to follow the gene's inheritance. This is especially useful in populations like the Italian and the Afrikaner, in which the two alleles are evenly represented. It is, in fact, possible to follow the inheritance of the defective allele from heterozygous patients (42.9% in our study) and thus unequivocally diagnose FH in early infancy in nearly one-third of the patients (Table 5) .
One interesting point is the association between the P1 allele and FH. The single point mutation generating the extra Pvu II site does not seem, by itself, to adversely affect the LDL receptor gene function, since the plasma concentrations of total cholesterol and LDL cholesterol were not significantly different among the P1P1, P1P2, and P2P2 groups. Thus, the most likely explanation is that a mutation causing FH occurred on a chromosome that lacked the cutting site for Pvu II, and that this mutation makes a significant contribution to the pool of mutation causing FH in the Italian population. This would suggest the existence of a founder effect as is seen in the Afrikaner population. 18 Although Pvu II identifies an individual at risk in only 32.5% of FH cases, it is certainly a step toward an early and unequivocal diagnosis of this disease. If different RFLPs of the LDL receptor that can be used to split the Pvu II alleles are identified, it will be possible to more accurately follow the inheritance of the disease and to eventually offer an early diagnosis in most, if not all, families with FH. Some promising RFLPs have, indeed, been recently reported with Ava II, Apa LI, and (2) P1P2 (1) P1P1 (1) P1P1 (1) P1P1 (1) P1P2 (1) P1P2 (1) P1P1 ( The number in parenthesis is the number of subjects. 'Cases in which Pvu II RFLP allows unequivocal diagnosis of health or disease without knowledge of plasma cholesterol level. tAmbiguous families.
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